Comparison of the clinical features of all 701 patients with AL amyloidosis according to availability of baseline SF-36 data
Feature . | SF-36 completed; n = 544 . | SF-36 unavailable; n = 157 . | P . |
|---|---|---|---|
| Age, y, mean | 60.4 ± 10.6 | 60.0 ± 12.0 | .712 |
| Mo from first symptom to diagnosis* | 8.1 (3.2, 15.57) | 7.9 (3.5, 17.9) | .369 |
| Mo from diagnosis to referral* | 2.7 (1.5, 6.5) | 3.1 (1.6, 7.8) | .256 |
| Performance status greater than 1, %† | 39.4 | 48.9 | .027 |
| Number of organ systems involved* | 3 (2, 4) | 3 (2, 4) | .476 |
| Organ involvement, % | |||
| Heart | 52.4 | 56.1 | .418 |
| Kidney | 80.2 | 80.9 | .836 |
| Gastrointestinal/liver | 61.8 | 64.3 | .559 |
| Neuropathy | 52.0 | 52.9 | .852 |
| Soft tissue | 23.4 | 22.9 | .914 |
Feature . | SF-36 completed; n = 544 . | SF-36 unavailable; n = 157 . | P . |
|---|---|---|---|
| Age, y, mean | 60.4 ± 10.6 | 60.0 ± 12.0 | .712 |
| Mo from first symptom to diagnosis* | 8.1 (3.2, 15.57) | 7.9 (3.5, 17.9) | .369 |
| Mo from diagnosis to referral* | 2.7 (1.5, 6.5) | 3.1 (1.6, 7.8) | .256 |
| Performance status greater than 1, %† | 39.4 | 48.9 | .027 |
| Number of organ systems involved* | 3 (2, 4) | 3 (2, 4) | .476 |
| Organ involvement, % | |||
| Heart | 52.4 | 56.1 | .418 |
| Kidney | 80.2 | 80.9 | .836 |
| Gastrointestinal/liver | 61.8 | 64.3 | .559 |
| Neuropathy | 52.0 | 52.9 | .852 |
| Soft tissue | 23.4 | 22.9 | .914 |